Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mahamaya LifesciencesBOM:544611 +0.33%16 Return-on-Tangible-Equity is 22.14% as of Mar. 2026, which is 28% below its 10-year median of 30.65. GuruFocus rates BOM:544611 with a GF Score™ of 16/100. The stock has 4 warning signs investors should review. Among 249 Agriculture companies, Mahamaya Lifesciences ranks better than 59.44% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Mahamaya Lifesciences's annualized net income for the quarter that ended in Mar. 2026 was ₹163 Mil. Mahamaya Lifesciences's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹737 Mil. Therefore, Mahamaya Lifesciences's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 22.14%.
The historical rank and industry rank for Mahamaya Lifesciences's Return-on-Tangible-Equity or its related term are showing as below:
BOM:544611'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 11.07 Med: 30.65 Max: 43.8
Current: 11.07
During the past 5 years, Mahamaya Lifesciences's highest Return-on-Tangible-Equity was 43.80%. The lowest was 11.07%. And the median was 30.65%.
BOM:544611's Return-on-Tangible-Equity is ranked better than 59.44% of 249
companies
in the Agriculture industry
Industry Median: 7.18
vs BOM:544611: 11.07
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Mahamaya Lifesciences Return-on-Tangible-Equity Related Terms
Mahamaya Lifesciences Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Mahamaya Lifesciences's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544611 vs CTVA, CF, MOS: Return-on-Tangible-Equity Comparison
For the Agricultural Inputs subindustry, Mahamaya Lifesciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mahamaya Lifesciences Return-on-Tangible-Equity vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Mahamaya Lifesciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Mahamaya Lifesciences's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 22.14% mean?
Mahamaya Lifesciences (BOM:544611) has a Return-on-Tangible-Equity of 22.14% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Mahamaya Lifesciences and its competitors. This is 28% below median its historical median of 30.65. Over the past decade, Mahamaya Lifesciences' Return-on-Tangible-Equity has ranged from 11.07 to 43.80. According to the industry distribution chart, Mahamaya Lifesciences ranks #101 out of 249 companies in the Agriculture industry, placing it in the top 40.6%.
Is Mahamaya Lifesciences' Return-on-Tangible-Equity too high?
Mahamaya Lifesciences' current Return-on-Tangible-Equity of 22.14% is 28% below median its 10-year median of 30.65. Over the past 10 years, this metric has ranged from a low of 11.07 to a high of 43.80. The Agriculture industry median Return-on-Tangible-Equity is 7.18. Mahamaya Lifesciences' value of 22.14% is 208.4% above this industry median. Based on the distribution chart, Mahamaya Lifesciences ranks #101 out of 249 companies in the Agriculture industry, which is above the industry midpoint. Overall, Mahamaya Lifesciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Mahamaya Lifesciences' Return-on-Tangible-Equity compare to CTVA and CF?
According to the Agriculture industry distribution chart, Mahamaya Lifesciences ranks #101 out of 249 companies for Return-on-Tangible-Equity. This puts Mahamaya Lifesciences in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.18. Mahamaya Lifesciences' value of 22.14% is 208.4% above this benchmark. Historically, Mahamaya Lifesciences' own Return-on-Tangible-Equity has ranged from 11.07 to 43.80 over the past decade. While the company's 10-year median is 30.65 vs. the industry median of 7.18, Mahamaya Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for an Agriculture company?
The median Return-on-Tangible-Equity among Agriculture companies is 7.18, based on 249 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mahamaya Lifesciences's current Return-on-Tangible-Equity of 22.14% is 208.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Mahamaya Lifesciences and its competitors. For the Agriculture industry, the median Return-on-Tangible-Equity is 7.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mahamaya Lifesciences's current Return-on-Tangible-Equity is 22.14%, which is 28% below median its own 10-year median of 30.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mahamaya Lifesciences stock overvalued right now?
Mahamaya Lifesciences (BOM:544611) has a current Return-on-Tangible-Equity of 22.14%. The current Return-on-Tangible-Equity is 22.14%, which is 28% below median its 10-year median of 30.65 and 208.4% above the Agriculture industry median of 7.18. Mahamaya Lifesciences' overall GF Score™ is 16/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Mahamaya Lifesciences (BOM:544611), the current Return-on-Tangible-Equity is 22.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mahamaya Lifesciences Ltd specializes in the manufacturing of pesticide formulations and supplies bulk formulations catering to both Indian agrochemical companies as well as multinational corporations (MNCs). The company's offerings include Insecticides, Herbicides, and Fungicides. Geographically, it serves multiple Indian states including Punjab, Haryana, Rajasthan, and Uttar Pradesh, and internationally serves countries like the Dominican Republic, Turkey, Egypt, and the UAE. The company generates revenue from the sale of its pesticide formulations.
16GF Score
Get the complete analysis for BOM:544611
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544611 has been successfully added to your 
